Compare PAYX & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYX | IQV |
|---|---|---|
| Founded | 1979 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Business Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8B | 35.1B |
| IPO Year | 1995 | 2013 |
| Metric | PAYX | IQV |
|---|---|---|
| Price | $113.55 | $208.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 16 |
| Target Price | $111.67 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 3.0M | 1.2M |
| Earning Date | 03-25-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.59% | N/A |
| EPS Growth | ★ 6.77 | 4.67 |
| EPS | ★ 4.89 | 1.61 |
| Revenue | $6,512,000,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $19.19 | $6.77 |
| Revenue Next Year | $5.50 | $5.89 |
| P/E Ratio | ★ $22.63 | $128.77 |
| Revenue Growth | 16.88 | ★ 41.60 |
| 52 Week Low | $85.45 | $154.50 |
| 52 Week High | $148.11 | $247.05 |
| Indicator | PAYX | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 65.55 | 62.78 |
| Support Level | $108.28 | $206.72 |
| Resistance Level | $117.78 | $212.36 |
| Average True Range (ATR) | 2.99 | 5.79 |
| MACD | 0.10 | -0.87 |
| Stochastic Oscillator | 75.11 | 62.72 |
Paychex is a cloud-based human capital management provider offering payroll, compliance, talent management, benefits administration, and retirement services. The firm also provides HR outsourcing services, including professional employer organization, or PEO, offerings, enabling clients to reduce HR overhead. Paychex primarily targets small and midsize businesses, although its acquisition of Paycor in 2025 signals the firm's aspirations to expand into the midmarket segment, serving firms with more than 100 employees. As of fiscal 2026, Paychex has approximately 800,000 clients and manages payroll for one in 11 workers in the United States.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.